ALL
Filters
All Videos
Insights from 2025 Tandem Annual Meeting
Tandem 2025 Insights: Management of Steroid Refractory Acute GVHD
FEATURING
David Jacobsohn
- 2 views
- March 10, 2025
Total Health
CAR T-Cell Therapy Innovations in ALL and CLL
FEATURING
Nitin Jain
- 2 views
- March 10, 2025
Nicholas Short
Clinical Use of MRD in Adult ALL: Recommendations From a Panel of U.S. Experts
- 10 views
- February 28, 2025
OncoPharm
Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinical Pearls
FEATURING
John Bossaer
- 18 views
- February 14, 2025
GRACE
HSCT & Cell Therapy 101: Overview of Types, Processes, Supportive Care, and Toxicities
FEATURING
Muhammad Salman Faisal
- 20 views
- February 6, 2025
Louisville Hematology Highlights
CAR-T Therapies: Outpatient Administration and Care
FEATURING
Joseph Maakaron
- 6 views
- January 31, 2025
Louisville Hematology Highlights
Optimization of BMT and Cellular Therapy Inpatient Care
FEATURING
Corinne Shamehdi
- 14 views
- January 31, 2025
Elisabetta Xue
Identifying Steroid-Refractory or Steroid-Dependent cGVHD and the Role of Ruxolitinib
- 49 views
- January 30, 2025
GRACE
Common Toxicities Associated With Allogeneic HSCT
FEATURING
Muhammad Salman Faisal
- 11 views
- January 30, 2025
Moffitt Cancer Center
Infectious Disease Perspective of CAR T-Cell Therapy
FEATURING
Aliyah Baluch
- 108 views
- January 28, 2025
- 1
Roswell Park Comprehensive Cancer Center
Steroid-Refractory GVHD Updates
FEATURING
Shernan Holtan
- 192 views
- January 24, 2025
City of Hope
Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancements in Treatment With Corticosteroids & JAK Inhibitors
FEATURING
Amandeep Salhotra
- 97 views
- January 22, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph- ALL
FEATURING
Fadi Haddad
- 162 views
- January 21, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph+ ALL
FEATURING
Fadi Haddad
- 112 views
- January 21, 2025
- 1
ecancer
ASH 2024 Insights: Blinatumomab + Chemo in Newly Diagnosed NCI Standard Risk Pediatric B-ALL - Ph3 COG AALL1731 Trial
FEATURING
Rachel Rau
- 9 views
- January 21, 2025
Louisville Hematology Highlights
2024 Review of Frontline Treatment in ALL
FEATURING
Nicholas Short
- 62 views
- January 21, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dose Optimization of Inotuzumab Ozogamicin in Adult Patients With R/R ALL
FEATURING
Daniel J. DeAngelo
- 32 views
- January 15, 2025
- 1
Northwestern Medicine Oncology and Hematology
Approach to MRD in T-Cell ALL
FEATURING
Shira Dinner
- 19 views
- December 30, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dasatinib + Inotuzumab Ozogamicin-Based Induction for 1L Ph+ ALL
FEATURING
Anand Patel
- 35 views
- December 30, 2024
- 1
Giuseppe Francesco Milone
The Evolving Landscape of cGVHD Treatment Options
- 44 views
- December 27, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AML, MDS, and ALL
FEATURING
Talha Badar
- 1,216 views
- December 24, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Adult ALL and Implications for Practice
FEATURING
Ryan Cassaday
- 330 views
- December 23, 2024
- 6
University of Illinois Cancer Center
Emerging Induction and Consolidation Regimens in ALL
FEATURING
John Quigley
- 7 views
- December 20, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in Newly Diagnosed NCI Standard Risk Pediatric B-ALL
FEATURING
Sumit Gupta
- 163 views
- December 19, 2024
- 2
Oncology 2024 Year in Review
Year in Review 2024 - Transformative FDA Approvals in Precision Oncology Across Various Cancer Types
FEATURING
Vivek Subbiah
- 2,808 views
- December 17, 2024
- 8
Winship Cancer Institute - Emory University
FDA Approved First Oral Solution of Imatinib
FEATURING
Aseala Abousaud
- 54 views
- December 13, 2024
- 1
Muhammad Abid
Infectious Complications in Pts Receiving CD19 vs. BCMA Targeted CAR-T Therapy
- 19 views
- December 10, 2024
- 1
Total Health
Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist
FEATURING
Sarah Medeiros
- 281 views
- November 26, 2024
- 2
Noah Merin
Axatilimab in cGVHD: Mechanism of Action and Comparison With Current Therapeutic Agents
- 123 views
- November 10, 2024
ecancer
Transplantation in Adult ALL: Current Guidelines and Key Considerations
FEATURING
Sameer Tulpule
- 42 views
- October 30, 2024
Yale Cancer Center
B-ALL Case Discussion: Management of Relapsed Ph- Disease
- 32 views
- October 29, 2024
Marina Konopleva
Considering Venetoclax in AML and ALL - Which Patients and Why
- 69 views
- October 23, 2024
- 2
Marlise R. Luskin
Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals
- 107 views
- October 21, 2024
- 2
Najla El-Jurdi
CSF1R's Role in Modulating Inflammation & Fibrosis in cGVHD
- 44 views
- October 16, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Pediatric ALL: Etiology, Diagnosis and Management
FEATURING
ÖZlem TüFekçI GüRocak
- 26 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient
FEATURING
Kubra Ozsoy
- 4 views
- October 15, 2024
Brittany Ragon
Targeting cGVHD: Mechanism of Action of Axatilimab Compared to Other Available Agents
- 30 views
- October 14, 2024
Masonic Cancer Center, University of Minnesota
The Genetic Epidemiology and Early-Life Origins of Childhood Leukemia
FEATURING
Adam de Smith
- 10 views
- October 8, 2024
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 39 views
- October 7, 2024
Cleveland Clinic Taussig Cancer Institute
R/R B-ALL Case Discussion: Managing Toxicities of Immunotherapies
FEATURING
Bassam Estfan,
Paolo Caimi
- 29 views
- October 3, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Ph+ ALL Management: Case-Based Discussion
FEATURING
Kivanc Koruk
- 23 views
- September 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With R/R ALL
FEATURING
Elias Jabbour
- 44 views
- September 27, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 584 views
- September 23, 2024
- 2
University of Colorado Department of Medicine
Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Going?
FEATURING
Jonathan Gutman
- 481 views
- September 19, 2024
- 5
Talha Badar
Updates in ALL: Incorporating Immunotherapy in Frontline Management
- 282 views
- September 16, 2024
- 3
Daniel Wolff
The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibrosis in cGVHD – Recently FDA Approved
- 173 views
- September 6, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients
FEATURING
Dieter Hoelzer
- 31 views
- September 6, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patients
FEATURING
Elias Jabbour
- 44 views
- September 6, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: CML, AML, ALL
FEATURING
Mariam Nawas
- 45 views
- September 3, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Incorporation of Targeted and Immunotherapies in ALL
FEATURING
Hagop Kantarjian
- 234 views
- August 30, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxicity Management
FEATURING
Ebru Erdogan
- 15 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
B-ALL Case Discussion: Frequent Viral Infections and Multiple Relapses
FEATURING
Cansu Hemsinlioglu
- 17 views
- August 30, 2024
MyCancerHaven
Incorporating Blinatumomab and Inotuzumab Into 1L ALL Treatment
FEATURING
Ravi Vij,
Nicholas Short
- 181 views
- August 30, 2024
- 2
MyCancerHaven
Hematopoetic Stem Cell Transplant: How I Decide
FEATURING
Ravi Vij,
Sanghee Hong
- 100 views
- August 30, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
The Importance of MRD in ALL
FEATURING
Farhad Ravandi
- 187 views
- August 29, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Approaches to Managing T-Cell ALL
FEATURING
Ahmad Ibrahim
- 49 views
- August 28, 2024
Salman Fazal
Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience
- 215 views
- August 27, 2024
- 3
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of Persistently MRD+ ALL
FEATURING
Asli Odabasi Giden
- 37 views
- August 15, 2024
Robert Zeiser
CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD
- 61 views
- August 13, 2024
- 1
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
ALL in Adults: Overview and Recent Advances
FEATURING
Ryan Cassaday
- 253 views
- August 13, 2024
- 2
Sarah Tasian
Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorporation Into Practice
- 527 views
- August 9, 2024
- 5
University of Colorado Cancer Center
Frontline Treatment of ALL: Current Standards and Emergence of CAR-T
FEATURING
Marc Schwartz
- 72 views
- August 1, 2024
Giuseppe Francesco Milone
Steroid-Refractory GvHD Management: When to Switch From Steroids
- 96 views
- August 1, 2024
UChicago Medicine
Understanding CRISPR and Gene Editing in the Treatment of Heme Malignancies and Blood Disorders
FEATURING
Alan Cooper
- 263 views
- July 29, 2024
ecancer
Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients Undergoing MMUD HCT
FEATURING
Monzr Al Malki,
Steven Devine
- 48 views
- July 24, 2024
Vanderbilt University Medical Center (VUMC)
Prevention and Management of Post-SCT Relapse in Acute Leukemias
FEATURING
Andrew Jallouk
- 283 views
- July 18, 2024
- 6
SOHO Brazil 2024
How Are Targeted Therapies Redefining the Treatment Paradigm in ALL in Adults
FEATURING
Jan Burger
- 128 views
- July 11, 2024
- 1
University of Colorado Division of Hematology
Case-Based Insights on Managing Adults With R/R ALL
FEATURING
Marc Schwartz
- 61 views
- July 3, 2024
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell Therapy
FEATURING
Mark Hamilton
- 224 views
- June 28, 2024
- 3
Insights from 2024 EHA Annual Meeting
Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL
FEATURING
Jose-Maria Ribera
- 107 views
- June 24, 2024
- 1
James Essell
Bringing CAR-T for Hematologic Malignancies to the Community Practices
- 75 views
- June 20, 2024
2024 ASCO® Annual Meeting Insights Hub
Understanding New Strategies to Prevent and Manage Chronic GVHD
FEATURING
Betty Hamilton
- 112 views
- June 16, 2024
- 1
Icahn School of Medicine at Mount Sinai
Navigating aGVHD Treatment: Integrating Recent Updates in Clinical Management
FEATURING
James Ferrara
- 84 views
- May 31, 2024
Rush University Medical Center
[duplicate] Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- May 29, 2024
Rush University Medical Center
Cellular Therapy Strategies for Persistent Disease After Induction for B-ALL
FEATURING
Vinod Pullarkat
- 62 views
- May 29, 2024
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- 346 views
- May 29, 2024
- 4
Rush University Medical Center
Selection and Sequencing of Chronic GVHD Therapy
FEATURING
Satyajit Kosuri
- 301 views
- May 24, 2024
- 1
Yale Cancer Center
Summary of Promising Recent Studies in LR-MDS, HR-MDS, and R/R AML
FEATURING
Rory Shallis
- 92 views
- May 16, 2024
Yale Cancer Center
Summary of Recent Advances in Adult ALL
FEATURING
Lourdes Mendez
- 140 views
- May 15, 2024
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: Adult Ph- B-ALL With Hypodiploidy, TP53mut and CDKN2A Loss
FEATURING
Mercy Anyanwu
- 167 views
- May 6, 2024
- 1
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies
FEATURING
David Reeves
- 251 views
- April 30, 2024
- 2
Tisch Cancer Institute at Mount Sinai
Early T-Cell Precursor ALL Case Discussion: Diagnosis, Prognosis, and Treatment Options
FEATURING
Ariel Siegel
- 118 views
- April 29, 2024
Fred Hutchinson Cancer Center
Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and Beyond
FEATURING
Ryan Cassaday
- 552 views
- April 29, 2024
- 4
MyCancerHaven
Treating Adults With Newly Diagnosed ALL
FEATURING
Ravi Vij,
Anand Patel
- 447 views
- April 26, 2024
- 4
Indy Hematology Review
Treatment Strategies in MDS and ALL: Removing Bad Humor & Targeting Aberrant Signaling
FEATURING
Richard Stone
- 185 views
- April 22, 2024
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 974 views
- April 16, 2024
- 5
Elias Jabbour
CRS and ICANS With BiTEs in ALL - How to Manage With Dose Adjustments
- 230 views
- April 10, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: ALL
FEATURING
Elias Jabbour
- 207 views
- March 29, 2024
Zachariah DeFilipp
Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study
- 244 views
- March 27, 2024
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
FEATURING
Noopur S. Raje
- 485 views
- March 15, 2024
- 1
Yale Cancer Center
Targeting Apoptosis in Leukemia: Lessons and Challenges
FEATURING
Marina Konopleva
- 111 views
- March 15, 2024
- 1
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Targeted Strategies
FEATURING
Idoroenyi Amanam
- 221 views
- March 11, 2024
- 1
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Lymphoid Diseases
- 50 views
- March 11, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
FEATURING
Catherine Lai
- 554 views
- March 11, 2024
- 3
2024 Clinical Case Studies
Clinical Case Review: A Not-So-Sweet Case of Vulvar Ulceration
FEATURING
Amaris Geisler
- 627 views
- March 6, 2024
- 3
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 148 views
- February 27, 2024
- 2
Louisville Hematology Highlights
Current Approaches in the Frontline Treatment of Adult ALL
FEATURING
Nicholas Short
- 150 views
- February 26, 2024
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
FEATURING
Robert Peter Gale
- 4,721 views
- February 26, 2024
- 21
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
FEATURING
Robert Peter Gale
- 514 views
- February 21, 2024
- 2
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Febrile Neutropenia in Patients With Cancer
FEATURING
Şiran Keske
- 77 views
- February 21, 2024
- 1
Insights from 2023 ASH Annual Meeting
Clinically-Relevant Updates in ALL in Adults
FEATURING
Ryan Cassaday
- 263 views
- February 20, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
HSCT Post CAR-T in Hematologic Malignancies: To Transplant or Not to Transplant
FEATURING
Koray YalçIn
- 22 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Is HSCT Necessary to Consolidate Hematological Remission After CAR-T in ALL?
FEATURING
Francesco Saglio
- 44 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
BK Virus Infections in Pediatric Leukemia During Treatment
FEATURING
Dilek KaçAr
- 17 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current Status and Future Directions for CAR T-Cell Therapy
FEATURING
Jean-Francois Rossi
- 30 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Inaticabtagene Autoleucel Treatment in Adult R/R B-Cell ALL in China
FEATURING
Lyu Lulu
- 9 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current and Future Approaches to the Treatment of B- and T-ALL
FEATURING
Dieter Hoelzer
- 35 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
The Truth About Current Consensus Statements on Hematopoietic Cell Transplant
FEATURING
Robert Peter Gale
- 539 views
- February 15, 2024
- 2
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Role of ASCT in Treatment of R/R Lymphoma Patients in Resource Limited Countries
FEATURING
Adriatik Berisha
- 15 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Adults With ALL: When Not to Transplant
FEATURING
Elias Jabbour
- 38 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Adults With ALL: When to Transplant
FEATURING
Sabina Chiaretti
- 20 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Feasibilty of Therapy for Elderly Ph+ ALL Patients
FEATURING
Giovanni Marconi
- 25 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Recent Updates in ALL Treatment
FEATURING
Giovanni Martinelli
- 22 views
- February 15, 2024
Masonic Cancer Center, University of Minnesota
ALL: The Changing Shape of MRD
FEATURING
Sean Tracy
- 101 views
- January 24, 2024
Insights from 2023 ASH Annual Meeting
AML and MDS Highlights & Key Takeaways
FEATURING
Talha Badar
- 2,236 views
- January 24, 2024
- 14
ecancer
ASH 2023 Insights: "PhALLCON Study - Ponatinib vs. Imatinib in Patients With Newly Diagnosed Ph+ ALL"
FEATURING
Elias Jabbour
- 54 views
- January 19, 2024
ecancer
ASH 2023 Insights: "AUGMENT-101 - Revumenib Monotherapy in Pts With R/R KMT2Ar Acute Leukemia"
FEATURING
Ibrahim Aldoss
- 59 views
- January 18, 2024
- 1
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
FEATURING
Amy Zhou
- 955 views
- January 8, 2024
- 6
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults With ND Ph- B-ALL or T-ALL"
FEATURING
Marlise R. Luskin
- 180 views
- December 29, 2023
- 2
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Venetoclax With Inotuzumab Ozogamicin for R/R ALL in Adults"
FEATURING
Marlise R. Luskin
- 25 views
- December 29, 2023
Insights from 2023 ASH Annual Meeting
Chronic GVHD: Results from Agave-201 - Axatilimab at 3 Different Doses
FEATURING
Daniel Wolff
- 109 views
- December 29, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2Ar Acute Leukemia From the AUGMENT-101 Study"
FEATURING
Ibrahim Aldoss
- 102 views
- December 29, 2023
UNC Lineberger Comprehensive Cancer Center
CAR-T 101: Overview of CAR-T Therapy and Management of Toxicities
FEATURING
Megan Mcelfresh
- 192 views
- December 28, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "PROs From BMT CTN 1703 Study in GVHD Prophylaxis - a QoL Evaluation"
FEATURING
Shernan Holtan
- 27 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "AYAs With ALL - Treatment Approaches and Ongoing Challenges"
FEATURING
Emily Curran
- 58 views
- December 19, 2023
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
FEATURING
Douglas Tremblay
- 436 views
- December 13, 2023
- 1
5th SOHO Italy Annual Conference
SOHO Italy 2023: The Pathogenesis of Acute Leukemias - Approaches and Molecular Insights
FEATURING
Ilaria Iacobucci
- 44 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Digital Droplet PCR in Hematologic Malignancies - A New Useful Molecular Tool
FEATURING
Sara Galimberti
- 33 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: The First Approved Academic CAR-T in Europe
FEATURING
Julio Delgado
- 21 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Developing Academic CAR-T Therapy - The Role of The Translational Researcher
FEATURING
Massimiliano Mazza
- 31 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Overcome Resistance to New Cell Therapies in Pediatric ALL
FEATURING
Concetta Quintarelli
- 121 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage Complications After CAR-T & Bispecific Antibodies - A Perspective From the ICU
FEATURING
Giuliano Bolondi
- 125 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: CAR-T vs Allo Transplantation in R/R ALL
FEATURING
Josep-Maria Ribera
- 17 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Management of Infectious Complications in ALL Patients Treated With Novel Therapies
FEATURING
Livio Pagano
- 33 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: FLT3 Alterations & Inhibition in Adults With Triple Negative B-ALL
FEATURING
Anna Ferrari
- 60 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: A New Conditioning Regimen Pre-Allogeneic Stem Cell Transplantation
FEATURING
Jean El-Cheikh
- 88 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: New Developments in ALL Treatment - An Italian Perspective
FEATURING
Giovanni Martinelli
- 13 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Management of Newly Diagnosed Ph+ ALL - Novel Drugs and Strategies
FEATURING
Elias Jabbour
- 17 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: GIMEMA in ALL - Past, Present and Future
FEATURING
Robert Foa
- 16 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Synergy of Verapamil With Everolimus in T-ALL Cells
FEATURING
Micol Silic-Benussi
- 6 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Synergistic Antitumor Activity of MTORC1 and BCL-2 Inhibitors in Pediatric T-Cell ALL
FEATURING
Loredana Urso
- 8 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How to Better Integrate Monoclonal Antibodies in the Current Therapy of ALL Patients
FEATURING
Daniela Cilloni
- 16 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Cellular Therapies in Adult ALL - What’s New?
FEATURING
Nitin Jain
- 18 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Current Approach to Ph-Like ALL
FEATURING
Marina Konopleva
- 50 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: MRD by NGS in ALL
FEATURING
Giovanni Martinelli
- 23 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Prognostic and Therapeutic Implications of MRD in ALL
FEATURING
Naval Daver,
Elias Jabbour
- 30 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: ALL - Progress in Research and Therapy
FEATURING
Hagop Kantarjian
- 30 views
- November 25, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat the Older Adult With Ph- ALL
FEATURING
Elias Jabbour
- 27 views
- November 25, 2023
Cleveland Clinic Rheumatology
Taming the T-Cell and Prospects for CAR T-Cell Therapy
FEATURING
Georg Schett
- 56 views
- November 15, 2023
UNC Lineberger Comprehensive Cancer Center
Let’s Take a BiTE Out of CRS and Neurotoxicity
FEATURING
Bejal Kikani
- 228 views
- November 10, 2023
- 1
MyCancerHaven
Experts Discuss the Basics of CAR-Ts in ALL
FEATURING
Ravi Vij,
Bijal Shah
- 52 views
- November 7, 2023
- 1
University of Colorado Division of Hematology
Overview of the Immune System and Immunotherapy in Blood Cancers
FEATURING
Heather Knowles
- 93 views
- October 24, 2023
- 2
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board at the Tisch Cancer Institute at Mount Sinai: 73 y/o Female With Ph+ B-ALL Converting from MRD- to MRD+
FEATURING
Megan Metzger,
Fredrick Henry,
John Mascarenhas,
Jonathan Feld,
Lisa Brailey,
Kathryn Johnson,
Hannah Levavi,
Joseph Tripodi
- 66 views
- October 24, 2023
UNC Lineberger Comprehensive Cancer Center
UNC Updates on Caring for Older Adults With Acute Leukemia in 2023
FEATURING
Daniel Richardson
- 84 views
- October 23, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: Cellular Therapy
FEATURING
Marcos de Lima
- 55 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
Next Questions in ALL
FEATURING
Elias Jabbour
- 178 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: CNS Prophylaxis in ALL
FEATURING
Partow Kebriaei
- 33 views
- October 18, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Sequencing Immunotherapies in Adults With B-ALL
FEATURING
Bijal Shah
- 48 views
- October 18, 2023
- 1
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T
FEATURING
Jae Park
- 87 views
- October 18, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Slow-Motion Therapeutic Revolution in Adult ALL
FEATURING
Hagop Kantarjian
- 104 views
- October 6, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 First Report of Phase 3 PhALLCON Study: Comparing Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL
FEATURING
Elias Jabbour
- 117 views
- October 4, 2023
- 1